On this page
The field notes
A dedicated BPC-157 page is useful, but its $99/month headline and $297 ten-week protocol describe different units. Compare the actual protocol total, then ask how any later purchase would be priced.
What is on the record
- Dedicated product entry names the proposed preparation.
- A specific purchase period and total are published.
Read the small print
- A public listing does not establish a clinical outcome or personal eligibility.
- The retrieved no-prescription payment policy needs a written answer.
Open the published facts
- Published offering
- BPC-157 subcutaneous injectable listing; patient-specific assessment required.
- Starting price
- $297 for the displayed ten-week protocol; the page also uses a $99/month headline.
- Billing & renewal
- Read the selected product’s purchase period and renewal terms in the review.
- Verification scope
- Exact pharmacy assignment, individual licensure and dispensed-product quality not independently verified.
Partner link. We may earn a commission.
Read the unit attached to the number
The dedicated BPC-157 page gives a ten-week protocol total alongside a monthly headline. Ten weeks is not three calendar months. Use the actual purchase period when you put this offer beside a monthly refill or a three-month package. Ask whether any repeat order would be another complete protocol or a different service arrangement.
A named product is a beginning
The listing describes a subcutaneous preparation. Before comparing value, obtain the actual ingredient form, concentration, amount supplied and dispensing pharmacy. A product name does not establish any of those fields. The essential guide helps keep formulation and route attached to the evidence instead of borrowing a result from a different preparation.
Ask what happens if care does not begin
The retrieved refund policy leaves the no-prescription payment answer unresolved. Request a written explanation before paying, including whether any assessment charge remains if the clinician declines treatment. Use the consultation checklist for the clinical questions and keep purchase-policy questions in the same correspondence.
The ten-week label is not a recovery prediction
A package duration is a commercial description. It does not establish when an injury would improve, whether treatment is appropriate or whether a study supports the proposed use. Pepti provides another reviewed service model to compare, while the BPC-157 evidence guide explains the difference between a preclinical finding and a patient outcome.
References & product documents
The evidence and service information used here.
- Live Vital: dedicated product recordCompany website
- Live Vital: published refund policyCompany website
- Live Vital: state availabilityCompany website